Study On The Efficacy And Safety Of Telbivudine In Blocking Mother-to-child Transmission Of Hepatitis B Virus

Purpose On the basis of previous passive and passive immunization of pregnant women with hepatitis B,the mother was treated with anti-hepatitis B virus again,and the efficacy and safety of telbivudine to block mother-to-child transmission of hepatitis B virus were further explored.The basis for the solution is provided.Object and method We selected 60 patients with positive hepatitis B surface antigen(HBsAb)and hepatitis B virus gene(HBV-DNA)>1.0x106 IU/ml in the outpatient department of Shenyang Medical College affiliated to Shenyang Medical College and the Shengjing Hospital affiliated to China Medical University from 2015 to 2018.They were divided into 2 groups and 40 experimental groups.Pregnant women started oral telbivudine antiviral treatment 600mg/day at 24 weeks of gestation,and 20 pregnant women in the control group did not receive anti-HBV treatment.Serum hepatitis B surface antigen(HBsAg),serum hepatitis B virus(HBV-DNA)levels,alanine aminotransferase(ALT)were compared between the two groups of pregnant women at 24 weeks of gestation,before delivery,4 weeks after delivery,and 24 weeks after delivery.),Aspartate aminotransferase(AST),Creatinine(CR),Creatine Kinase-MB(CK-MB),Prothrombin(PT),and fetal heart rate during pregnancy There were differences between the experimental group and the control group.The Apgar score,gestational age,body weight,and HBV-DNA and HBsAg indicators at 7 months after birth were compared.ResultThe positive rate of HBsAg in the newborns in the experimental group was 0%in July,and the positive rate in HBsAg in the control group was 10%in July.The success rate of HBV blocking in the experimental group was significantly higher than that in the control group.The difference was statistically significant(?2 value)=4.1 38,P<0.05);the DNA load of hepatitis B in the experimental group was significantly lower than that in the untreated group after the antiviral treatment with telbivudine.Compared with the HBV-DNA of the experimental group,the difference was statistically significant(P<0.05).There was no significant difference in the safety indexes between the two groups of pregnant women and children(P>0.05).ConclusionIn the middle and late pregnancy,pregnant women with high hepatitis B virus load can effectively block the intrauterine transmission of hepatitis B virus by oral administration of telbivudine,and the risk of adverse reactions is not increased for mothers and infants,and the safety is good.